Claims for Patent: 10,695,308

Summary for Patent: 10,695,308

Title:	Inhalation formulations of treprostinil
Abstract:	The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
Inventor(s):	Wade; Michael (Chapel Hill, NC)
Assignee:	United Therapeutics Corporation (Silver Spring, MD)
Application Number:	16/131,248
Patent Claims:	1. A method of treating a human patient suffering from pulmonary hypertension, comprising: providing an infusion solution comprising 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt or ester thereof, and intravenously administering the infusion solution to the human patient at a rate of from 0.625 to 50 ng/kg/min, wherein the infusion solution is sterile and isotonic with blood. 2. The method of claim 1, wherein the infusion solution is administered at a rate of 0.1 ml/min/kg. 3. The method of claim 1, wherein the rate of administration is from 10 to 15 ng/kg/min.